Beta Bionics, Inc. Common Stock (BBNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beta Bionics, Inc. Common Stock (BBNX) has a cash flow conversion efficiency ratio of -0.088x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.83 Million) by net assets ($271.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Beta Bionics, Inc. Common Stock to measure how many days the company can operate on defensive assets alone.
Beta Bionics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Beta Bionics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Beta Bionics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beta Bionics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GuangDong GenSho Logistics Co
SHG:603813
|
-0.033x |
|
Groupe CRIT SA
PA:CEN
|
0.112x |
|
Gemtek Technology Co Ltd
TW:4906
|
0.095x |
|
BELL AGROMACHINA ORD T (BSE)
NSE:BALUFORGE
|
0.032x |
|
Chatham Lodging Trust REIT
NYSE:CLDT
|
0.018x |
|
Movado Group Inc
NYSE:MOV
|
0.014x |
|
Floridienne
BR:FLOB
|
0.106x |
|
AnShan Heavy Duty Mining Machinery Co Ltd
SHE:002667
|
0.106x |
Annual Cash Flow Conversion Efficiency for Beta Bionics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Beta Bionics, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see Beta Bionics, Inc. Common Stock stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $287.61 Million | $-50.92 Million | -0.177x | +72.12% |
| 2024-12-31 | $76.01 Million | $-48.27 Million | -0.635x | -14.72% |
| 2023-12-31 | $58.61 Million | $-32.45 Million | -0.554x | +88.05% |
| 2022-12-31 | $13.00 Million | $-60.21 Million | -4.631x | -- |
About Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Pa… Read more